Victory Capital Management Inc. Has $15.48 Million Stock Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Victory Capital Management Inc. decreased its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 15.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 193,185 shares of the company's stock after selling 36,410 shares during the quarter. Victory Capital Management Inc. owned about 0.37% of PROCEPT BioRobotics worth $15,478,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Values First Advisors Inc. bought a new stake in PROCEPT BioRobotics during the third quarter worth approximately $27,000. Mark Sheptoff Financial Planning LLC bought a new stake in PROCEPT BioRobotics during the second quarter worth approximately $36,000. Quest Partners LLC boosted its position in PROCEPT BioRobotics by 2,492.3% during the second quarter. Quest Partners LLC now owns 674 shares of the company's stock worth $41,000 after purchasing an additional 648 shares during the period. Nisa Investment Advisors LLC boosted its position in PROCEPT BioRobotics by 178.3% during the third quarter. Nisa Investment Advisors LLC now owns 1,113 shares of the company's stock worth $89,000 after purchasing an additional 713 shares during the period. Finally, Sentry Investment Management LLC bought a new stake in PROCEPT BioRobotics during the third quarter worth approximately $120,000. Institutional investors own 89.46% of the company's stock.

Insider Transactions at PROCEPT BioRobotics

In related news, CFO Kevin Waters sold 25,000 shares of the firm's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $82.51, for a total value of $2,062,750.00. Following the transaction, the chief financial officer now owns 96,096 shares in the company, valued at $7,928,880.96. This trade represents a 20.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Antal Rohit Desai sold 35,220 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $76.12, for a total value of $2,680,946.40. Following the completion of the transaction, the director now owns 23,963 shares in the company, valued at approximately $1,824,063.56. This represents a 59.51 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 535,353 shares of company stock worth $46,627,426. Insiders own 17.40% of the company's stock.

PROCEPT BioRobotics Price Performance

PROCEPT BioRobotics stock traded down $0.87 during mid-day trading on Wednesday, hitting $92.70. 433,585 shares of the company were exchanged, compared to its average volume of 659,946. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The business has a fifty day moving average of $81.88 and a 200 day moving average of $72.08. PROCEPT BioRobotics Co. has a 1-year low of $31.57 and a 1-year high of $103.81. The company has a market capitalization of $4.84 billion, a PE ratio of -47.54 and a beta of 1.01.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Monday, October 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.09. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The firm had revenue of $58.40 million during the quarter, compared to analyst estimates of $53.30 million. During the same period in the prior year, the company posted ($0.51) earnings per share. The business's revenue for the quarter was up 66.4% compared to the same quarter last year. As a group, sell-side analysts expect that PROCEPT BioRobotics Co. will post -1.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Piper Sandler reaffirmed an "overweight" rating and set a $75.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, October 8th. Wells Fargo & Company upped their price target on PROCEPT BioRobotics from $67.00 to $69.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. TD Cowen upped their price target on PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Truist Financial reiterated a "buy" rating and set a $105.00 price target (up from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. Finally, Jefferies Financial Group started coverage on PROCEPT BioRobotics in a report on Thursday, November 14th. They set a "hold" rating and a $95.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $89.50.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).